No Data
No Data
Cantor Fitzgerald Maintains Mereo BioPharma(MREO.US) With Buy Rating, Maintains Target Price $7
Mereo BioPharma Group Price Target Maintained With a $7.00/Share by Cantor Fitzgerald
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
AM Best Assigns Credit Ratings to Mereo Insurance Limited
Mereo Insurance Limited Launches Into Attractive Reinsurance Market
Buy Recommendation for Mereo Biopharma Group Plc Driven by Promising Clinical Programs and Strategic Positioning